Ovarian, fallopian tube and peritoneal cancer (BRCA 1 or 2, mutated, relapsed, platinum-sensitive) - olaparib (maintenance) [ID735]: committee papers1

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer – AstraZeneca

03 - PAS Submission from the technology manufacturer – AstraZeneca

04 - NICE request to the manufacturer for clarification on their submission

05 - Manufacturer clarification response

06 - Consultee submission - British Gynaecological Cancer Society

07 - Consultee submission - Ovarian Cancer Action

08 - Consultee submission – Ovacome

09 - Consultee submission - Target Ovarian Cancer

10 - Consultee submission - Royal College of Pathologists

11 - Consultee submission - Royal College of Physicians

12 - Patient expert personal perspective – Dean

13 - Patient expert personal perspective – Newman

14 - Clinical expert personal perspective – Gourley

15 - Clinical expert personal perspective – Ledermann

16 - Evidence Review Group report prepared by School of Health and Related Research

17 - Evidence Review Group report - Addendum prepared by School of Health and Related Research

18 - Manufacturer factual accuracy check of Evidence Review Group report

19 - Evidence Review Group response to the  factual accuracy check

20 - Evidence Review Group replacement pages for the report

21 - Evidence Review Group report - Erratum prepared by School of Health and Related Research

22 - Company statement for consideration by the Appraisal Committee

This page was last updated: 07 August 2015